Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 40 years of age~* Kellgren \& Lawrence grade I-III~* If there is more than one knee having a weight bearing pain of at least 40mm evaluated by 100mm VAS~* Be willing to discontinue all nonsteroidal anti-inflammatory drugs(NSAIDs), analgesics, condroichin sulfate/glucosamine or physical therapy for the duration of the study~Exclusion Criteria:~* Body mass index \> 32~* Have rheumarthritis~* Patients who have a weight-bearing pain of less than 40mm on both knees when measured by 100mm-VAS~* Have Sudek's atrophy, Paget's disease, Spinal disc herniation~* Kellgren \& Lawrence Grade IV

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and then LBSA0103 (Type: EXPERIMENTAL): The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
- Hyruan Plus (Type: ACTIVE_COMPARATOR): The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.

Based on this trial design, predict the completion outcome and termination type (if applicable).